Pharsight

Tegsedi patents expiration

TEGSEDI IPR and PTAB Proceedings
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7015315 AKCEA THERAPS Gapped oligonucleotides
Mar, 2023

(1 year, 2 months ago)

US7101993 AKCEA THERAPS Oligonucleotides containing 2′-O-modified purines
Sep, 2023

(9 months ago)

US8101743 AKCEA THERAPS Modulation of transthyretin expression
Apr, 2025

(9 months from now)

US9061044 AKCEA THERAPS Modulation of transthyretin expression
Apr, 2031

(6 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9399774 AKCEA THERAPS Modulation of transthyretin expression
Apr, 2031

(6 years from now)

US8697860 AKCEA THERAPS Diagnosis and treatment of disease
Apr, 2031

(6 years from now)

Tegsedi is owned by Akcea Theraps.

Tegsedi contains Inotersen Sodium.

Tegsedi has a total of 6 drug patents out of which 2 drug patents have expired.

Expired drug patents of Tegsedi are:

  • US7015315
  • US7101993

Tegsedi was authorised for market use on 05 October, 2018.

Tegsedi is available in solution;subcutaneous dosage forms.

Tegsedi can be used as treatment of polyneuropathy of hereditary transthyretin amyloidosis.

Drug patent challenges can be filed against Tegsedi from 05 October, 2022.

The generics of Tegsedi are possible to be released after 29 April, 2031.

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity(ODE-212) Oct 05, 2025
New Chemical Entity Exclusivity(NCE) Oct 05, 2023

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

Drugs and Companies using INOTERSEN SODIUM ingredient

NCE-1 date: 05 October, 2022

Market Authorisation Date: 05 October, 2018

Treatment: Treatment of polyneuropathy of hereditary transthyretin amyloidosis

Dosage: SOLUTION;SUBCUTANEOUS

More Information on Dosage

TEGSEDI family patents

Family Patents